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OBJECTIVES The present study examined the effect on forearm endothelial function of an angiotensin II
type 1 receptor antagonist, losartan, in subjects with non-insulin-dependent diabetes mellitus
(NIDDM).
BACKGROUND Angiotensin-converting enzyme (ACE) inhibition with enalapril improves acetylcholine
(ACh)-dependent endothelial function in patients with NIDDM. This could be mediated
through angiotensin II and the type 1 receptor or could be due to inhibition of kininase II and
a bradykinin preserving effect. It is therefore relevant to determine whether a type 1 receptor
antagonist improves endothelial function.
METHODS The influence of losartan (50 mg daily for four weeks) on endothelium-dependent and
independent vasodilator function was determined in 9 NIDDM subjects using a double-
blinded placebo-controlled crossover protocol. Forearm blood flow was measured using
strain-gauge plethysmography.
RESULTS Losartan significantly decreased infused arm vascular resistance in response to three
incremental doses of intrabrachial acetylcholine (p , 0.05, ANOVA). The forearm blood
flow ratio (flow in infused to noninfused arm) was also increased (p , 0.01). Responses to
sodium nitroprusside and monomethyl arginine were not significantly changed.
CONCLUSIONS Losartan administration at 50 mg per day improved endothelium-dependent dilation of
resistance vessels in patients with NIDDM. That is, blockade of the angiotensin II type 1
receptors improves endothelial function in NIDDM. At least some of the similarly beneficial
effect of ACE inhibition is probably mediated also through the angiotensin II-type 1 receptor
pathway. The use of a type 1 receptor antagonist seems a reasonable alternative to an ACE
inhibitor to maintain endothelial function in NIDDM subjects. (J Am Coll Cardiol 2000;36:
1461–6) © 2000 by the American College of Cardiology
Angiotensin-converting enzyme (ACE) inhibitors improve
endothelial NO-related vasodilator function in patients
with depressed function, including those with both insulin-
dependent (1) and non-insulin-dependent (2) diabetes mel-
litus (NIDDM). The mechanisms are not well defined and
may involve greater NO production and/or reduced NO
inactivation by oxygen-derived free radicals (3) or by other
compounds. Since the introduction of angiotensin II type 1
receptor blocking drugs there has been considerable specu-
lation on the relative merits of these drugs and ACE
inhibitors, especially in hypertension (4–6) and cardiac
failure (7). The receptor blocking drugs can potentially
produce greater inhibition of effects mediated by angioten-
sin II. During the administration of a competitive ACE
inhibitor, angiotensin II can still be produced from angio-
tensin I, probably attributable both to the higher concen-
trations of angiotensin I that accompany ACE inhibition
and to conversion by other enzyme systems such as chymase.
In contrast, type 1 receptor inhibition with currently used
drugs is partly noncompetitive, or insurmountable, although
the degree varies with the particular inhibitor. Furthermore,
it is speculated that type 1 receptor inhibition might result
in buildup of angiotensin II with stimulation of type 2
receptors and beneficial effects. These considerations would
favor the type 1 receptor blocking drugs over ACE inhibi-
tors. On the other hand, ACE inhibitors additionally
inhibit the breakdown of bradykinin, and there is consider-
able evidence that increase in release of NO, induced by the
accumulation of bradykinin, contributes to the augmented
endothelium dependent vasodilator responses resulting from
ACE inhibition (8–12).
As a clear improvement in endothelium-dependent vaso-
dilation has been found to result from four weeks adminis-
tration of the ACE inhibitor, enalapril, in NIDDM (2), it
was of interest to examine the effect of the type 1 receptor
antagonist, losartan in a similar group.
METHODS
Subjects. Nine subjects (7 men, 2 women, average age
54 6 2 years) with NIDDM without evidence of microvas-
cular or macrovascular complications were recruited. They
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undertook a screening program consisting of a medical
history and examination, and a hematological and biochem-
ical profile, including measurement of blood glucose, gly-
cated hemoglobin, serum electrolytes, urea and creatinine,
uric acid, liver function and serum lipids. The following
were excluded: smokers, those with renal impairment or
proteinuria, hepatic impairment, gout or hyperuricemia,
more than mild hypercholesterolemia (total cholesterol
.6.0 mmol/l) or hypertension (systolic BP .160 mm Hg).
The average time since diagnosis of diabetes was 5 6 1
years. None of the patients were receiving lipid-lowering
therapy or taking vitamin supplements or ACE inhibitors.
Eight patients were taking metformin and, additionally, two
were taking glibenclamide and one metformin plus glipiz-
ide. Medications remained unchanged during the study.
None had significant microalbuminuria on quantitative
assessment (24-h excretion using nephelometric method) or
significant retinopathy (full-field photography). The mean
glycated hemoglobin at entry was 7.6 6 0.5% (normal
range 5 4.3% to 6.0%), indicating moderate to good
glycemic control. The study protocol was approved by the
Royal Perth Hospital Ethics Committee and subjects gave
written, informed consent.
Study design. The effect of four weeks of angiotensin II
type 1 receptor blockade was studied using a randomized,
double-blind, placebo-controlled crossover protocol. Sub-
jects were randomized to receive losartan 50 mg daily
(Merck, Sharp & Dohme, Australia) or a similarly packaged
placebo. The validity of the active drug/placebo randomiza-
tion was checked by tablet analysis using an HPLC quali-
tative method. Forearm vascular function was studied after
four weeks, following which crossover of therapy occurred
with restudy four weeks later. The procedures were con-
ducted, on average, 3.0 6 0.6 h after the study medication
and, for individual subjects, at the same time of the day for
the repeat study after crossover. Subjects were required to
refrain from drinking alcohol or caffeine-containing bever-
ages for 12 h before the procedure. At each visit the
biochemical and hematological parameters were repeated.
There were no adverse side effects.
Vascular function assessment. Investigations were con-
ducted in a quiet, temperature-controlled laboratory with
subjects lying supine and both forearms supported above
heart level. A 20-gauge arterial cannula (Arrow, Reading,
Pennsylvania) was introduced into the brachial artery of the
nondominant arm under local anesthesia with ,2 ml of 1%
lidocaine (Astra Pharmaceuticals, Australia) to transduce
pressure, for the infusion of drugs or physiological saline
and for sampling of arterial blood. Forearm blood flow
(FBF, ml/100 ml forearm/min) was measured simulta-
neously in both arms by gallium/indium strain gauge
(SG24, Medasonics, Mountain View, California) plethys-
mography. Wrist cuffs, connected to a flow-regulated source
of compressed air, and arm cuffs, connected to a rapid
inflation device (E20, D.E. Hokanson, Bellevue, W.A.,
Australia), were placed on each limb. Output from the
strain gauges passed through an amplifier (SPG 16, Meda-
sonics) and was sampled by an on-line microcomputer at
75 Hz before being displayed on a monitor in real time. A
software program coordinated the acquisition, storage and
display of data as well as inflation and deflation of the arm
cuffs, ensuring that blood flow measures were synchronized
with cuff inflation during recording periods. Intra-arterial
pressure was measured continuously (Transpac, Abbot Lab-
oratories, Illinois) throughout the study. Drug infusions
were administered using a constant rate infusion pump
(IVAC 770, IVAC Corporation, California) in the protocol
indicated below.
Baseline measurements started at least 25 min after
cannulation of the brachial artery. Blood flow measurements
were taken by inflating the wrist cuffs to 220 mm Hg to
exclude the hands from the circulation, and by rapidly
inflating the upper arm cuffs to 45 mm Hg for 10 out of
every 15 s throughout the baseline and drug infusion
periods. Output from the strain gauges was stored and the
average of the last five flow measurements from each period
was used for analysis. Between infusions, the cuffs were
deflated, allowing at least 15 min for forearm blood flow to
recover from the preceding infusion before further baseline
measures were recorded.
All solutions were prepared aseptically from sterile stock
solutions or ampoules immediately before infusion into the
brachial artery. Acetylcholine (ACh; Miochol; Johnson &
Johnson, Australia) was infused at 10, 20 and 40 mg/min
each for 3 min, followed by sodium nitroprusside (SNP;
David Bull Laboratories, Australia) at 2, 4 and 8 mg/min
each for 3 min, and then NG-monomethyl-L-arginine
(LNMMA; Clinalfa, Switzerland) at 2, 4 and 8 mmol/min
each for 5 min.
Analysis. Although the low doses of drugs infused in the
study produce negligible systemic effects and showed no
effect on blood pressure or heart rate, it is still desirable to
account for any possible variation in overall hemodynamics
as a cause of the flow changes seen in the infused forearm.
Thus, FBF was measured simultaneously in both arms,
although only one arm was infused, and the noninfused arm
served as a control. As in earlier studies (1,2), forearm blood
flow in the infused arm is described as a ratio to that in the
non-infused arm. Changes in these ratios during ACh, SNP
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
ACh 5 acetylcholine
FBF 5 forearm blood flow
FMD 5 flow mediated dilation
FVR 5 forearm vascular resistance
LDL 5 low density lipoprotein
LNMMA5 NG-monomethyl-L-arginine
NIDDM5 noninsulin-dependent diabetes mellitus
NO 5 nitric oxide
SNP 5 sodium nitroprusside
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and LNMMA infusions are expressed as percentage
changes from the baseline immediately preceding each drug
administration. In addition, FBF is expressed in absolute
units (ml/100 ml/min), and vascular resistance was calcu-
lated in the infused arm as the ratio of mean arterial pressure
to forearm blood flow and expressed in the units mm Hg per
ml/100 ml tissue/min. All blood flow measures were ana-
lyzed by two blinded investigators.
Results are expressed as means 6 SE. The responses after
losartan therapy were compared to placebo responses using
two-way analysis of variance (ANOVA) with repeated
measures performed on the three dose levels of ACh, SNP
and LNMMA. Responses at each level of drug infusion
were compared using Student t test (two-sided). A p value
of ,0.05 was considered statistically significant.
RESULTS
There were no differences in blood glucose, glycated hemo-
globin or serum lipids between losartan and placebo treat-
ment (Table 1). Although blood pressure was lower at the
time of FBF measurement following losartan therapy, the
difference was of borderline statistical significance (p 5
0.05).
Absolute FBF data recorded in the infused and nonin-
fused limbs at baseline and during the infusion of ACh,
SNP and LNMMA at three dose levels during placebo and
losartan administration, are presented in Table 2. There was
a trend to a greater increase in absolute FBF in the infused
limb in response to ACh after losartan than after placebo,
but this did not reach significance (p 5 0.08, ANOVA; p 5
0.08, 0.18, 0.10, by t tests respectively at low, intermediate
and high ACh infusion rates). Although the data suggest a
trend toward a greater response to SNP, this was not
significant (p 5 0.2, ANOVA; p 5 0.29, 0.09, 0.24 by t
tests) and the response to LNMMA was not altered by
losartan (p 5 0.5, ANOVA; p 5 0.19, 0.57, 0.97). When
the infused limb data were expressed in terms of forearm
vascular resistance (FVR, Table 3), losartan was associated
with a significant increase in the response to ACh (p 5
0.04, ANOVA; p 5 0.03, 0.17, 0.14) and the responses to
SNP and LNMMA were not significantly altered (p 5 0.2,
ANOVA; p 5 0.35, 0.16, 0.27 for SNP and p 5 0.6,
ANOVA; p 5 0.11, 0.49, 0.76 for LNMMA).
As described in the Methods, it is optimal to analyze the
data in terms of FBF ratios, that is, the ratio of flow in the
infused arm to that in the noninfused arm, and to refer these
to the similarly derived baseline ratios preceding each set of
drug infusions. Figures 1 through 3 present the percentage
changes in these ratios from their baselines, in response to
ACh, SNP and LNMMA. Losartan administration signif-
icantly augmented responses to ACh (p 5 0.01, ANOVA;
p , 0.02, ,0.02, ,0.05 at the 3 dose levels, respectively),
while there were no differences in response to SNP (p 5 0.6,
ANOVA; p . 0.4 at each infusion level by t tests) or
Table 1. Subject Characteristics During Placebo and
Losartan Administration
Placebo Losartan
Blood glucose (mmol.L21) 7.7 6 1.4 8.0 6 1.4
Glycosylated hemoglobin (%) 7.6 6 0.5 7.7 6 0.5
Plasma lipids (mmol.L21)
Total cholesterol 4.6 6 0.2 4.4 6 0.2
LDL-C 2.7 6 0.1 2.6 6 0.2
HDL-C 1.1 6 0.1 1.1 6 0.1
Triglycerides 1.7 6 0.2 1.7 6 0.2
Mean arterial pressure (mm Hg) 86 6 4* 80 6 4*
Resting heart rate (beats/min) 67 6 3 71 6 3
Values are means 6 SE. *p 5 0.05 for difference; no significant differences in other
variables.
Table 2. Absolute FBF Responses in the Infused and Noninfused Arms After Losartan and
Placebo Treatment
Infused Arm Flows Noninfused Arm Flows
Placebo Losartan Placebo Losartan
Resting FBF 2.04 6 0.23 2.37 6 0.30 1.92 6 0.16 2.19 6 0.27
ACh infusion
10 mg/min 4.49 6 1.44 7.04 6 1.79 2.04 6 0.27 1.93 6 0.24
20 mg/min 5.92 6 1.32 8.08 6 1.60 2.15 6 0.28 2.03 6 0.22
40 mg/min 8.21 6 1.69 12.59 6 2.34 2.17 6 0.31 2.06 6 0.26
Pre-SNP baseline 2.21 6 0.29 2.44 6 0.39 2.05 6 0.31 2.00 6 0.27
SNP infusion
2 mg/min 6.40 6 0.75 8.18 6 1.43 1.97 6 0.32 2.22 6 0.24
4 mg/min 7.94 6 1.10 11.84 6 1.70 1.88 6 0.24 2.12 6 0.21
8 mg/min 11.85 6 1.72 15.52 6 2.22 2.01 6 0.30 1.94 6 0.25
Pre-LNMMA baseline 2.16 6 0.25 2.61 6 0.25 1.95 6 0.27 2.38 6 0.16
LNMMA infusion
2 mmol/min 1.48 6 0.19 1.87 6 0.34 2.09 6 0.30 2.06 6 0.25
4 mmol/min 1.40 6 0.13 1.52 6 0.26 2.24 6 0.28 2.16 6 0.27
8 mmol/min 1.41 6 0.19 1.43 6 0.31 2.22 6 0.33 2.15 6 0.17
ACh 5 acetylcholine, LNMMA 5 NG-monomethyl-L-arginine, SNP 5 sodium nitroprusside. Values are means 6 SE in
ml/100 ml forearm/min. ACh, SNP and LNMMA responses were not significantly different following losartan therapy,
although there were trends to higher responses in the infused limb to ACh and SNP (ACh: p 5 0.08, ANOVA; p 5 0.08 at
10 mg/min, p 5 0.18 at 20 mg/min, p 5 0.10 at 40 mg/min, t tests; SNP: p 5 0.20, ANOVA; p 5 0.29, 0.09 and 0.24, t tests).
Responses to LNMMA were unchanged by losartan (p 5 0.5, ANOVA; p 5 0.19, 0.57, 0.97, t tests).
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LNMMA (p 5 0.5, ANOVA; p . 0.2 at each infusion
level).
DISCUSSION
Principal findings. Losartan in a dose of 50 mg once daily
has approximately the same effect on blood pressure in
hypertensives as does enalapril 20 mg daily (4,5). The effect
of losartan to improve Ach-stimulated vasodilator endothe-
lial function, which is largely NO-mediated, was compara-
ble to that found with enalapril in similar NIDDM subjects
(2).
Several authors have found endothelium-dependent re-
sponses to be depressed in NIDDM (13–16), but we did not
compare our subjects with a normal group.
Although the responses to SNP were not significantly
altered by losartan, they could be considered as equivocal in
terms of absolute FBF. Such would be consistent with
reports that endothelium-independent vasodilator responses
to SNP (14,15) and to glyceryl trinitrate (13) can also be
depressed in NIDDM. However, our SNP results do not
substantiate improvement in endothelium-independent di-
lation from losartan.
Pharmacokinetics of Losartan. The receptor inhibition of
losartan itself is competitive but that of its dominantly active
Figure 1. Forearm blood flow (FBF) response to three doses of acetylcho-
line (ACh) following placebo or losartan administration for four weeks.
Forearm blood flow is expressed as the percentage change in the ratio of
infusion arm to noninfusion arm flows relative to the baseline period
preceding the administration of ACh. Values are means 6 SE. ACh
response significantly increased following losartan administration (p ,
0.01, ANOVA; p , 0.02 at 10 mg/min, p , 0.02 at 20 mg/min, p , 0.05
at 40 mg/min, t tests).
Figure 2. Forearm blood flow (FBF) response to three doses of sodium
nitroprusside (SNP) following placebo or losartan administration for four
weeks. Forearm blood flow is expressed as the percentage change in the
ratio of infusion arm to noninfusion arm flows relative to the baseline
period preceding the administration of SNP. Values are means 6 SE. No
change in SNP response was evident following losartan administration
(p 5 0.6, ANOVA; at each infusion rate p . 0.4, t tests).
Figure 3. Forearm blood flow (FBF) response to three doses of NG
monomethyl-L-arginine (LNMMA) following placebo or losartan admin-
istration for four weeks. Forearm blood flow is expressed as the percentage
change in the ratio of infusion arm to noninfusion arm flows relative to the
baseline period preceding the administration of LNMMA. Values are
means 6 SE. No change in LNMMA response was evident following
losartan administration (p 5 0.5, ANOVA; at each infusion rate p . 0.2,
t tests).
Table 3. FVR Responses in the Infused Arm After Placebo and
Losartan Treatment
Placebo Losartan
Resting FVR 45.8 6 5.4 40.1 6 5.8
ACh infusion
10 mg/min 32.9 6 7.1 19.5 6 4.7
20 mg/min 23.7 6 6.6 16.2 6 3.9
40 mg/min 19.1 6 7.3 12.5 6 4.5
SNP infusion
2 mg/min 21.4 6 5.7 17.7 6 4.2
4 mg/min 18.7 6 5.0 14.2 6 5.2
8 mg/min 14.2 6 4.5 11.1 6 4.3
LNMMA infusion
2 mmol/min 68.4 6 9.6 57.2 6 11.3
4 mmol/min 67.0 6 7.0 60.8 6 9.4
8 mmol/min 68.4 6 7.6 72.9 6 12.5
Values are means 6 SE in mm Hg/ml/100 ml forearm/min. Vascular resistance was
significantly lower in response to ACh following losartan (p , 0.05, ANOVA; p 5
0.03 at 10 mg/min, p 5 0.17 at 20 mg/min, p 5 0.14 at 40 mg/min, t tests). SNP and
LNMMA responses were not significantly changed (SNP: p 5 0.2, ANOVA; p 5
0.33, 0.16, 0.27, t tests; LNMMA: p 5 0.6, ANOVA; p 5 0.11, p 5 0.49, p 5 0.76,
t tests).
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metabolite, which has a peak plasma concentration approx-
imately 3 h to 4 h after losartan administration, is partly
noncompetitive or insurmountable. Although the effect on
blood pressure in hypertensives is waning by 24 h, substan-
tial effect remains (5,6). Our studies of FBF would have
been conducted at a time of near maximum drug effect, as
indicated by the slightly lower blood pressure at the time of
the study conducted on losartan. Evidence has been pre-
sented by others that the hypotensive effect is not respon-
sible for the beneficial effect on endothelial function of ACE
inhibition with captopril (17).
Previous studies of type 1 receptor inhibition and endo-
thelial function. Although many clinical studies have
found ACE inhibition to improve endothelial function in a
variety of conditions (1,2,17–20), there have been few such
studies of the effect of type 1 receptor inhibition. In a recent
preliminary communication, improvement in flow-
mediated dilation (FMD) of the brachial artery, a largely
NO-dependent response, as is the dilator response to ACh,
was found after 2 months of losartan 25 or 50 mg daily in
patients with coronary artery disease (21).
Mechanism of action; inhibition of kininase II with ACE
inhibition. The role of the inhibition of kininase II and the
preservation of bradykinin in the beneficial actions of the
ACE inhibitors is controversial, but there is substantial
evidence that, in some circumstances, it is important (8–
12). Exposure of in vitro preparations to ACE inhibitors
greatly enhances exogenous bradykinin induced vascular
relaxation and acute ACE inhibition increases the coronary
vasodilation resulting from administration of bradykinin
into the human coronary circulation, an effect mediated
through NO (22). Furthermore, experimental administra-
tion of a bradykinin receptor inhibitor abolishes or greatly
reduces the potentiation by ACE inhibitors of muscarinic
induced endothelium dependent responses (8,10,12). It is
interesting to note that the inhibition of endothelium
dependent vasodilation by oxidized LDL is reversed by
ACE inhibition, the effect of which in the rat aorta was
reported to be abolished by bradykinin receptor inhibition
with HOE 140 (icatibrant), whereas losartan did not protect
against the effect of oxidized LDL (12). Finally, in favor of
an important action of ACE inhibition through bradykinin
and NO production, and most persuasively in man, the
bradykinin receptor inhibitor, icatibrant, not only substan-
tially reduced the hypotensive effect of captopril (23), but
completely abolished the increase in FMD of the radial
artery induced by acute ACE inhibition with quinaprilat
(11).
Mechanism of action; inhibition of superoxide produc-
tion with type 1 receptor and ACE inhibition. Despite
the above, a recent study suggests that ACE inhibition with
quinapril does not increase NO production but rather
decreases it; it is proposed that ACE inhibition reduces
superoxide production, leading to reduced inactivation of
NO and a compensatory decrease in NO production (24).
Enhanced inactivation of NO by superoxide is now consid-
ered to be a major mechanism for depression of NO-related
endothelial function (25). Superoxide production by mem-
brane NADPH/NADP oxidase is stimulated by angioten-
sin II, believed to be via the type 1 receptor. The increase in
superoxide production and depression of ACh-induced
vascular relaxation by angiotensin II has been found to be
inhibited by losartan (26), and angiotensin II macrophage-
mediated oxidation of LDL was inhibited by the receptor
antagonist saralasin (27). This evidence implicates a type 1
receptor and superoxide involvement in an angiotensin
II-induced deleterious effect on endothelial function and
provides an explanation for the beneficial effect of losartan.
At the same time, it does not deny additional involvement
of the bradykinin pathway in the action of ACE inhibition.
Other mechanisms relating endothelial function and
NIDDM. In NIDDM, additional mechanisms may be
operative to lead to depression of NO-related endothelial
function, including the inactivation of NO by advanced
glycation products as others have discussed (14). Also,
apparently, insulin can stimulate the production of NO
through the insulin receptor, the effector pathway having
some commonality with that for glucose transport (28).
Insulin resistance in NIDDM could lead to impaired NO
production, as could defective metabolism of tetrahydro-
biopterin. This compound is a cofactor for NO-synthase, its
concentration is reduced in the diabetic rat (29), its metab-
olism is dependent upon the oxidant state and it can
improve endothelial function in experimental diabetes (30).
Conclusions and implications. Even though the relative
importance of the various possible mechanisms leading to
depressed endothelial function in clinical NIDDM remains
to be elucidated, our study shows that blockade of the
angiotensin II type 1 receptor results in demonstrable
improvement. This would not necessarily pertain to other
conditions associated with depressed endothelial function in
which the mechanisms might be different. However, in
NIDDM, therapy with a type 1 receptor blocking drug
would appear to be a reasonable alternative to an ACE
inhibitor to maintain endothelial function. Such an ap-
proach could be particularly indicated in the presence of side
effects such as cough seen more frequently with ACE than
with type 1 receptor inhibition. Theoretical considerations
suggest that a combined approach, as suggested in the
management of other conditions, should be evaluated.
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